<?xml version="1.0"?>
<rss version="2.0">
 <channel>
  <title>StreetInsider.com News Articles</title>
  <link>http://www.streetinsider.com</link>
  <description>Latest StreetInsider.com News Articles</description>
  <language>en-us</language>
  <copyright>Copyright 2026, StreetInsider.com</copyright>
  <managingEditor>rss@streetinsider.com (SI RSS)</managingEditor>
  <webMaster>rss@streetinsider.com (SI RSS)</webMaster>
  <lastBuildDate>Wed, 10 Jun 2026 06:30:00 -0400</lastBuildDate>
  <docs>http://blogs.law.harvard.edu/tech/rss</docs>
  <image>
   <url>http://www.streetinsider.com/images/rss_logo.gif</url>
   <title>StreetInsider.com News Articles</title>
   <link>http://www.streetinsider.com</link>
   <width>143</width>
   <height>28</height>
  </image>
  <skipHours>
   <hour>0</hour>
   <hour>1</hour>
   <hour>2</hour>
   <hour>3</hour>
   <hour>21</hour>
   <hour>22</hour>
   <hour>23</hour>
  </skipHours>
  <skipDays>
   <day>Saturday</day>
   <day>Sunday</day>
  </skipDays>
  <item>
   <title>Immunic to Participate in Investor, Industry and Scientific Conferences in June</title>
   <link>http://www.streetinsider.com/Press+Releases/Immunic+to+Participate+in+Investor%2C+Industry+and+Scientific+Conferences+in+June/26626222.html</link>
   <description>
&lt;div class=&quot;xn-content&quot;&gt;
&lt;p&gt;&lt;span class=&quot;legendSpanClass&quot;&gt;&lt;location value=&quot;LU/us.ny.nyc&quot; idsrc=&quot;xmltag.org&quot; &gt;NEW YORK&lt;/location&gt;&lt;/span&gt;, &lt;span class=&quot;legendSpanClass&quot;&gt;&lt;chron&gt;June 10, 2026&lt;/chron&gt;&lt;/span&gt; /PRNewswire/ -- &lt;a target=&quot;_blank&quot; href=&quot;https://edge.prnewswire.com/c/link/?t=0&amp;amp;l=en&amp;amp;o=4707386-1&amp;amp;h=4194822939&amp;amp;u=https%3A%2F%2Fimux.com%2F&amp;amp;a=Immunic%2C+Inc.&quot; target=&quot;_blank&quot; rel=&quot;nofollow&quot;&gt;&lt;b&gt;&lt;span value=&quot;NASDAQ-NMS:IMUX&quot; idsrc=&quot;xmltag.org&quot; &gt;Immunic&lt;/span&gt;&lt;/b&gt;&lt;b&gt;, Inc.&lt;/b&gt;&lt;/a&gt;&lt;b&gt; (Nasdaq: IMUX)&lt;/b&gt;, a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases, today announced participation in the following investor, industry and scientific conferences in June:&lt;/p&gt;&lt;ul type=&quot;disc&quot;&gt;&lt;li&gt;&lt;chron&gt;June 15-16&lt;/chron&gt;: &lt;b&gt;&lt;person&gt;H.C. Wainwright&lt;/person&gt; 7th Annual Neuro Perspectives Expert Summit.&lt;/b&gt; Erik Lundgren, Chief Executive Officer of &lt;span value=&quot;NASDAQ-NMS:IMUX&quot; idsrc=&quot;xmltag.org&quot; &gt;Immunic&lt;/span&gt;, and &lt;person&gt;Jason Tardio&lt;/person&gt;, President and Chief Operating Officer of &lt;span value=&quot;NASDAQ-NMS:IMUX&quot; idsrc=&quot;xmltag.org&quot; &gt;Immunic&lt;/span&gt;, will participate in a fireside chat at this summit taking place in &lt;location value=&quot;LU/us.ny.nyc&quot; idsrc=&quot;xmltag.org&quot; &gt;New York&lt;/location&gt; and</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Press+Releases/Immunic+to+Participate+in+Investor%2C+Industry+and+Scientific+Conferences+in+June/26626222.html</guid>
   <pubDate>Wed, 10 Jun 2026 06:30:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">A.26221448</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">IMUX</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.01671603</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.02321652</category>
   	  </item>
  <item>
   <title>Immunic to Participate in Investor, Industry and Scientific Conferences in June</title>
   <link>http://www.streetinsider.com/Press+Releases/Immunic+to+Participate+in+Investor%2C+Industry+and+Scientific+Conferences+in+June/26626222.html</link>
   <description>
&lt;div class=&quot;xn-content&quot;&gt;
&lt;p&gt;&lt;span class=&quot;legendSpanClass&quot;&gt;&lt;location value=&quot;LU/us.ny.nyc&quot; idsrc=&quot;xmltag.org&quot; &gt;NEW YORK&lt;/location&gt;&lt;/span&gt;, &lt;span class=&quot;legendSpanClass&quot;&gt;&lt;chron&gt;June 10, 2026&lt;/chron&gt;&lt;/span&gt; /PRNewswire/ -- &lt;a target=&quot;_blank&quot; href=&quot;https://edge.prnewswire.com/c/link/?t=0&amp;amp;l=en&amp;amp;o=4707386-1&amp;amp;h=4194822939&amp;amp;u=https%3A%2F%2Fimux.com%2F&amp;amp;a=Immunic%2C+Inc.&quot; target=&quot;_blank&quot; rel=&quot;nofollow&quot;&gt;&lt;b&gt;&lt;span value=&quot;NASDAQ-NMS:IMUX&quot; idsrc=&quot;xmltag.org&quot; &gt;Immunic&lt;/span&gt;&lt;/b&gt;&lt;b&gt;, Inc.&lt;/b&gt;&lt;/a&gt;&lt;b&gt; (Nasdaq: IMUX)&lt;/b&gt;, a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases, today announced participation in the following investor, industry and scientific conferences in June:&lt;/p&gt;&lt;ul type=&quot;disc&quot;&gt;&lt;li&gt;&lt;chron&gt;June 15-16&lt;/chron&gt;: &lt;b&gt;&lt;person&gt;H.C. Wainwright&lt;/person&gt; 7th Annual Neuro Perspectives Expert Summit.&lt;/b&gt; Erik Lundgren, Chief Executive Officer of &lt;span value=&quot;NASDAQ-NMS:IMUX&quot; idsrc=&quot;xmltag.org&quot; &gt;Immunic&lt;/span&gt;, and &lt;person&gt;Jason Tardio&lt;/person&gt;, President and Chief Operating Officer of &lt;span value=&quot;NASDAQ-NMS:IMUX&quot; idsrc=&quot;xmltag.org&quot; &gt;Immunic&lt;/span&gt;, will participate in a fireside chat at this summit taking place in &lt;location value=&quot;LU/us.ny.nyc&quot; idsrc=&quot;xmltag.org&quot; &gt;New York&lt;/location&gt; and</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Press+Releases/Immunic+to+Participate+in+Investor%2C+Industry+and+Scientific+Conferences+in+June/26626222.html</guid>
   <pubDate>Wed, 10 Jun 2026 06:30:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">A.26221448</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">IMUX</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.01671603</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.02321652</category>
   	  </item>
  <item>
   <title>Immunic to Participate in Investor, Industry and Scientific Conferences in June</title>
   <link>http://www.streetinsider.com/Press+Releases/Immunic+to+Participate+in+Investor%2C+Industry+and+Scientific+Conferences+in+June/26626222.html</link>
   <description>
&lt;div class=&quot;xn-content&quot;&gt;
&lt;p&gt;&lt;span class=&quot;legendSpanClass&quot;&gt;&lt;location value=&quot;LU/us.ny.nyc&quot; idsrc=&quot;xmltag.org&quot; &gt;NEW YORK&lt;/location&gt;&lt;/span&gt;, &lt;span class=&quot;legendSpanClass&quot;&gt;&lt;chron&gt;June 10, 2026&lt;/chron&gt;&lt;/span&gt; /PRNewswire/ -- &lt;a target=&quot;_blank&quot; href=&quot;https://edge.prnewswire.com/c/link/?t=0&amp;amp;l=en&amp;amp;o=4707386-1&amp;amp;h=4194822939&amp;amp;u=https%3A%2F%2Fimux.com%2F&amp;amp;a=Immunic%2C+Inc.&quot; target=&quot;_blank&quot; rel=&quot;nofollow&quot;&gt;&lt;b&gt;&lt;span value=&quot;NASDAQ-NMS:IMUX&quot; idsrc=&quot;xmltag.org&quot; &gt;Immunic&lt;/span&gt;&lt;/b&gt;&lt;b&gt;, Inc.&lt;/b&gt;&lt;/a&gt;&lt;b&gt; (Nasdaq: IMUX)&lt;/b&gt;, a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases, today announced participation in the following investor, industry and scientific conferences in June:&lt;/p&gt;&lt;ul type=&quot;disc&quot;&gt;&lt;li&gt;&lt;chron&gt;June 15-16&lt;/chron&gt;: &lt;b&gt;&lt;person&gt;H.C. Wainwright&lt;/person&gt; 7th Annual Neuro Perspectives Expert Summit.&lt;/b&gt; Erik Lundgren, Chief Executive Officer of &lt;span value=&quot;NASDAQ-NMS:IMUX&quot; idsrc=&quot;xmltag.org&quot; &gt;Immunic&lt;/span&gt;, and &lt;person&gt;Jason Tardio&lt;/person&gt;, President and Chief Operating Officer of &lt;span value=&quot;NASDAQ-NMS:IMUX&quot; idsrc=&quot;xmltag.org&quot; &gt;Immunic&lt;/span&gt;, will participate in a fireside chat at this summit taking place in &lt;location value=&quot;LU/us.ny.nyc&quot; idsrc=&quot;xmltag.org&quot; &gt;New York&lt;/location&gt; and</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Press+Releases/Immunic+to+Participate+in+Investor%2C+Industry+and+Scientific+Conferences+in+June/26626222.html</guid>
   <pubDate>Wed, 10 Jun 2026 06:30:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">A.26221448</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">IMUX</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.01671603</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.02321652</category>
   	  </item>
  <item>
   <title>Immunic to Participate in Investor, Industry and Scientific Conferences in June</title>
   <link>http://www.streetinsider.com/Press+Releases/Immunic+to+Participate+in+Investor%2C+Industry+and+Scientific+Conferences+in+June/26626222.html</link>
   <description>
&lt;div class=&quot;xn-content&quot;&gt;
&lt;p&gt;&lt;span class=&quot;legendSpanClass&quot;&gt;&lt;location value=&quot;LU/us.ny.nyc&quot; idsrc=&quot;xmltag.org&quot; &gt;NEW YORK&lt;/location&gt;&lt;/span&gt;, &lt;span class=&quot;legendSpanClass&quot;&gt;&lt;chron&gt;June 10, 2026&lt;/chron&gt;&lt;/span&gt; /PRNewswire/ -- &lt;a target=&quot;_blank&quot; href=&quot;https://edge.prnewswire.com/c/link/?t=0&amp;amp;l=en&amp;amp;o=4707386-1&amp;amp;h=4194822939&amp;amp;u=https%3A%2F%2Fimux.com%2F&amp;amp;a=Immunic%2C+Inc.&quot; target=&quot;_blank&quot; rel=&quot;nofollow&quot;&gt;&lt;b&gt;&lt;span value=&quot;NASDAQ-NMS:IMUX&quot; idsrc=&quot;xmltag.org&quot; &gt;Immunic&lt;/span&gt;&lt;/b&gt;&lt;b&gt;, Inc.&lt;/b&gt;&lt;/a&gt;&lt;b&gt; (Nasdaq: IMUX)&lt;/b&gt;, a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases, today announced participation in the following investor, industry and scientific conferences in June:&lt;/p&gt;&lt;ul type=&quot;disc&quot;&gt;&lt;li&gt;&lt;chron&gt;June 15-16&lt;/chron&gt;: &lt;b&gt;&lt;person&gt;H.C. Wainwright&lt;/person&gt; 7th Annual Neuro Perspectives Expert Summit.&lt;/b&gt; Erik Lundgren, Chief Executive Officer of &lt;span value=&quot;NASDAQ-NMS:IMUX&quot; idsrc=&quot;xmltag.org&quot; &gt;Immunic&lt;/span&gt;, and &lt;person&gt;Jason Tardio&lt;/person&gt;, President and Chief Operating Officer of &lt;span value=&quot;NASDAQ-NMS:IMUX&quot; idsrc=&quot;xmltag.org&quot; &gt;Immunic&lt;/span&gt;, will participate in a fireside chat at this summit taking place in &lt;location value=&quot;LU/us.ny.nyc&quot; idsrc=&quot;xmltag.org&quot; &gt;New York&lt;/location&gt; and</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Press+Releases/Immunic+to+Participate+in+Investor%2C+Industry+and+Scientific+Conferences+in+June/26626222.html</guid>
   <pubDate>Wed, 10 Jun 2026 06:30:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">A.26221448</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">IMUX</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.01671603</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.02321652</category>
   	  </item>
  <item>
   <title>Immunic to Participate in Investor, Industry and Scientific Conferences in June</title>
   <link>http://www.streetinsider.com/PRNewswire/Immunic+to+Participate+in+Investor%2C+Industry+and+Scientific+Conferences+in+June/26626222.html</link>
   <description>
&lt;div class=&quot;xn-content&quot;&gt;
&lt;p&gt;&lt;span class=&quot;legendSpanClass&quot;&gt;&lt;location value=&quot;LU/us.ny.nyc&quot; idsrc=&quot;xmltag.org&quot; &gt;NEW YORK&lt;/location&gt;&lt;/span&gt;, &lt;span class=&quot;legendSpanClass&quot;&gt;&lt;chron&gt;June 10, 2026&lt;/chron&gt;&lt;/span&gt; /PRNewswire/ -- &lt;a target=&quot;_blank&quot; href=&quot;https://edge.prnewswire.com/c/link/?t=0&amp;amp;l=en&amp;amp;o=4707386-1&amp;amp;h=4194822939&amp;amp;u=https%3A%2F%2Fimux.com%2F&amp;amp;a=Immunic%2C+Inc.&quot; target=&quot;_blank&quot; rel=&quot;nofollow&quot;&gt;&lt;b&gt;&lt;span value=&quot;NASDAQ-NMS:IMUX&quot; idsrc=&quot;xmltag.org&quot; &gt;Immunic&lt;/span&gt;&lt;/b&gt;&lt;b&gt;, Inc.&lt;/b&gt;&lt;/a&gt;&lt;b&gt; (Nasdaq: IMUX)&lt;/b&gt;, a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases, today announced participation in the following investor, industry and scientific conferences in June:&lt;/p&gt;&lt;ul type=&quot;disc&quot;&gt;&lt;li&gt;&lt;chron&gt;June 15-16&lt;/chron&gt;: &lt;b&gt;&lt;person&gt;H.C. Wainwright&lt;/person&gt; 7th Annual Neuro Perspectives Expert Summit.&lt;/b&gt; Erik Lundgren, Chief Executive Officer of &lt;span value=&quot;NASDAQ-NMS:IMUX&quot; idsrc=&quot;xmltag.org&quot; &gt;Immunic&lt;/span&gt;, and &lt;person&gt;Jason Tardio&lt;/person&gt;, President and Chief Operating Officer of &lt;span value=&quot;NASDAQ-NMS:IMUX&quot; idsrc=&quot;xmltag.org&quot; &gt;Immunic&lt;/span&gt;, will participate in a fireside chat at this summit taking place in &lt;location value=&quot;LU/us.ny.nyc&quot; idsrc=&quot;xmltag.org&quot; &gt;New York&lt;/location&gt; and</description>
   <guid isPermaLink="true">http://www.streetinsider.com/PRNewswire/Immunic+to+Participate+in+Investor%2C+Industry+and+Scientific+Conferences+in+June/26626222.html</guid>
   <pubDate>Wed, 10 Jun 2026 06:30:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">A.26221448</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">IMUX</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.01671603</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.02321652</category>
   	  </item>
  <item>
   <title>Immunic to Participate in Investor, Industry and Scientific Conferences in June</title>
   <link>http://www.streetinsider.com/PRNewswire/Immunic+to+Participate+in+Investor%2C+Industry+and+Scientific+Conferences+in+June/26626222.html</link>
   <description>
&lt;div class=&quot;xn-content&quot;&gt;
&lt;p&gt;&lt;span class=&quot;legendSpanClass&quot;&gt;&lt;location value=&quot;LU/us.ny.nyc&quot; idsrc=&quot;xmltag.org&quot; &gt;NEW YORK&lt;/location&gt;&lt;/span&gt;, &lt;span class=&quot;legendSpanClass&quot;&gt;&lt;chron&gt;June 10, 2026&lt;/chron&gt;&lt;/span&gt; /PRNewswire/ -- &lt;a target=&quot;_blank&quot; href=&quot;https://edge.prnewswire.com/c/link/?t=0&amp;amp;l=en&amp;amp;o=4707386-1&amp;amp;h=4194822939&amp;amp;u=https%3A%2F%2Fimux.com%2F&amp;amp;a=Immunic%2C+Inc.&quot; target=&quot;_blank&quot; rel=&quot;nofollow&quot;&gt;&lt;b&gt;&lt;span value=&quot;NASDAQ-NMS:IMUX&quot; idsrc=&quot;xmltag.org&quot; &gt;Immunic&lt;/span&gt;&lt;/b&gt;&lt;b&gt;, Inc.&lt;/b&gt;&lt;/a&gt;&lt;b&gt; (Nasdaq: IMUX)&lt;/b&gt;, a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases, today announced participation in the following investor, industry and scientific conferences in June:&lt;/p&gt;&lt;ul type=&quot;disc&quot;&gt;&lt;li&gt;&lt;chron&gt;June 15-16&lt;/chron&gt;: &lt;b&gt;&lt;person&gt;H.C. Wainwright&lt;/person&gt; 7th Annual Neuro Perspectives Expert Summit.&lt;/b&gt; Erik Lundgren, Chief Executive Officer of &lt;span value=&quot;NASDAQ-NMS:IMUX&quot; idsrc=&quot;xmltag.org&quot; &gt;Immunic&lt;/span&gt;, and &lt;person&gt;Jason Tardio&lt;/person&gt;, President and Chief Operating Officer of &lt;span value=&quot;NASDAQ-NMS:IMUX&quot; idsrc=&quot;xmltag.org&quot; &gt;Immunic&lt;/span&gt;, will participate in a fireside chat at this summit taking place in &lt;location value=&quot;LU/us.ny.nyc&quot; idsrc=&quot;xmltag.org&quot; &gt;New York&lt;/location&gt; and</description>
   <guid isPermaLink="true">http://www.streetinsider.com/PRNewswire/Immunic+to+Participate+in+Investor%2C+Industry+and+Scientific+Conferences+in+June/26626222.html</guid>
   <pubDate>Wed, 10 Jun 2026 06:30:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">A.26221448</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">IMUX</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.01671603</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.02321652</category>
   	  </item>
  <item>
   <title>Immunic to Participate in Investor, Industry and Scientific Conferences in June</title>
   <link>http://www.streetinsider.com/PRNewswire/Immunic+to+Participate+in+Investor%2C+Industry+and+Scientific+Conferences+in+June/26626222.html</link>
   <description>
&lt;div class=&quot;xn-content&quot;&gt;
&lt;p&gt;&lt;span class=&quot;legendSpanClass&quot;&gt;&lt;location value=&quot;LU/us.ny.nyc&quot; idsrc=&quot;xmltag.org&quot; &gt;NEW YORK&lt;/location&gt;&lt;/span&gt;, &lt;span class=&quot;legendSpanClass&quot;&gt;&lt;chron&gt;June 10, 2026&lt;/chron&gt;&lt;/span&gt; /PRNewswire/ -- &lt;a target=&quot;_blank&quot; href=&quot;https://edge.prnewswire.com/c/link/?t=0&amp;amp;l=en&amp;amp;o=4707386-1&amp;amp;h=4194822939&amp;amp;u=https%3A%2F%2Fimux.com%2F&amp;amp;a=Immunic%2C+Inc.&quot; target=&quot;_blank&quot; rel=&quot;nofollow&quot;&gt;&lt;b&gt;&lt;span value=&quot;NASDAQ-NMS:IMUX&quot; idsrc=&quot;xmltag.org&quot; &gt;Immunic&lt;/span&gt;&lt;/b&gt;&lt;b&gt;, Inc.&lt;/b&gt;&lt;/a&gt;&lt;b&gt; (Nasdaq: IMUX)&lt;/b&gt;, a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases, today announced participation in the following investor, industry and scientific conferences in June:&lt;/p&gt;&lt;ul type=&quot;disc&quot;&gt;&lt;li&gt;&lt;chron&gt;June 15-16&lt;/chron&gt;: &lt;b&gt;&lt;person&gt;H.C. Wainwright&lt;/person&gt; 7th Annual Neuro Perspectives Expert Summit.&lt;/b&gt; Erik Lundgren, Chief Executive Officer of &lt;span value=&quot;NASDAQ-NMS:IMUX&quot; idsrc=&quot;xmltag.org&quot; &gt;Immunic&lt;/span&gt;, and &lt;person&gt;Jason Tardio&lt;/person&gt;, President and Chief Operating Officer of &lt;span value=&quot;NASDAQ-NMS:IMUX&quot; idsrc=&quot;xmltag.org&quot; &gt;Immunic&lt;/span&gt;, will participate in a fireside chat at this summit taking place in &lt;location value=&quot;LU/us.ny.nyc&quot; idsrc=&quot;xmltag.org&quot; &gt;New York&lt;/location&gt; and</description>
   <guid isPermaLink="true">http://www.streetinsider.com/PRNewswire/Immunic+to+Participate+in+Investor%2C+Industry+and+Scientific+Conferences+in+June/26626222.html</guid>
   <pubDate>Wed, 10 Jun 2026 06:30:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">A.26221448</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">IMUX</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.01671603</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.02321652</category>
   	  </item>
  <item>
   <title>Immunic to Participate in Investor, Industry and Scientific Conferences in June</title>
   <link>http://www.streetinsider.com/PRNewswire/Immunic+to+Participate+in+Investor%2C+Industry+and+Scientific+Conferences+in+June/26626222.html</link>
   <description>
&lt;div class=&quot;xn-content&quot;&gt;
&lt;p&gt;&lt;span class=&quot;legendSpanClass&quot;&gt;&lt;location value=&quot;LU/us.ny.nyc&quot; idsrc=&quot;xmltag.org&quot; &gt;NEW YORK&lt;/location&gt;&lt;/span&gt;, &lt;span class=&quot;legendSpanClass&quot;&gt;&lt;chron&gt;June 10, 2026&lt;/chron&gt;&lt;/span&gt; /PRNewswire/ -- &lt;a target=&quot;_blank&quot; href=&quot;https://edge.prnewswire.com/c/link/?t=0&amp;amp;l=en&amp;amp;o=4707386-1&amp;amp;h=4194822939&amp;amp;u=https%3A%2F%2Fimux.com%2F&amp;amp;a=Immunic%2C+Inc.&quot; target=&quot;_blank&quot; rel=&quot;nofollow&quot;&gt;&lt;b&gt;&lt;span value=&quot;NASDAQ-NMS:IMUX&quot; idsrc=&quot;xmltag.org&quot; &gt;Immunic&lt;/span&gt;&lt;/b&gt;&lt;b&gt;, Inc.&lt;/b&gt;&lt;/a&gt;&lt;b&gt; (Nasdaq: IMUX)&lt;/b&gt;, a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases, today announced participation in the following investor, industry and scientific conferences in June:&lt;/p&gt;&lt;ul type=&quot;disc&quot;&gt;&lt;li&gt;&lt;chron&gt;June 15-16&lt;/chron&gt;: &lt;b&gt;&lt;person&gt;H.C. Wainwright&lt;/person&gt; 7th Annual Neuro Perspectives Expert Summit.&lt;/b&gt; Erik Lundgren, Chief Executive Officer of &lt;span value=&quot;NASDAQ-NMS:IMUX&quot; idsrc=&quot;xmltag.org&quot; &gt;Immunic&lt;/span&gt;, and &lt;person&gt;Jason Tardio&lt;/person&gt;, President and Chief Operating Officer of &lt;span value=&quot;NASDAQ-NMS:IMUX&quot; idsrc=&quot;xmltag.org&quot; &gt;Immunic&lt;/span&gt;, will participate in a fireside chat at this summit taking place in &lt;location value=&quot;LU/us.ny.nyc&quot; idsrc=&quot;xmltag.org&quot; &gt;New York&lt;/location&gt; and</description>
   <guid isPermaLink="true">http://www.streetinsider.com/PRNewswire/Immunic+to+Participate+in+Investor%2C+Industry+and+Scientific+Conferences+in+June/26626222.html</guid>
   <pubDate>Wed, 10 Jun 2026 06:30:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">A.26221448</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">IMUX</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.01671603</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.02321652</category>
   	  </item>
  <item>
   <title>Form  4          IMMUNIC, INC.             For: May 22  Filed by: Lundgren Erik</title>
   <link>http://www.streetinsider.com/SEC+Filings/Form++4++++++++++IMMUNIC%2C+INC.+++++++++++++For%3A+May+22++Filed+by%3A+Lundgren+Erik/26585358.html</link>
   <description>si-local-file:///var/storage/secattach/20260601/26585358.html</description>
   <guid isPermaLink="true">http://www.streetinsider.com/SEC+Filings/Form++4++++++++++IMMUNIC%2C+INC.+++++++++++++For%3A+May+22++Filed+by%3A+Lundgren+Erik/26585358.html</guid>
   <pubDate>Mon, 01 Jun 2026 17:57:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">IMUX</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.02321652</category>
   	  </item>
  <item>
   <title>Form  4          IMMUNIC, INC.             For: May 22  Filed by: Lundgren Erik</title>
   <link>http://www.streetinsider.com/SEC+Filings/Form++4++++++++++IMMUNIC%2C+INC.+++++++++++++For%3A+May+22++Filed+by%3A+Lundgren+Erik/26585358.html</link>
   <description>si-local-file:///var/storage/secattach/20260601/26585358.html</description>
   <guid isPermaLink="true">http://www.streetinsider.com/SEC+Filings/Form++4++++++++++IMMUNIC%2C+INC.+++++++++++++For%3A+May+22++Filed+by%3A+Lundgren+Erik/26585358.html</guid>
   <pubDate>Mon, 01 Jun 2026 17:57:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">IMUX</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.02321652</category>
   	  </item>
  <item>
   <title>Form  3          IMMUNIC, INC.             For: Jun 01  Filed by: Lundgren Erik</title>
   <link>http://www.streetinsider.com/SEC+Filings/Form++3++++++++++IMMUNIC%2C+INC.+++++++++++++For%3A+Jun+01++Filed+by%3A+Lundgren+Erik/26585352.html</link>
   <description>si-local-file:///var/storage/secattach/20260601/26585352.html</description>
   <guid isPermaLink="true">http://www.streetinsider.com/SEC+Filings/Form++3++++++++++IMMUNIC%2C+INC.+++++++++++++For%3A+Jun+01++Filed+by%3A+Lundgren+Erik/26585352.html</guid>
   <pubDate>Mon, 01 Jun 2026 17:56:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">IMUX</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.02321652</category>
   	  </item>
  <item>
   <title>Form  3          IMMUNIC, INC.             For: Jun 01  Filed by: Lundgren Erik</title>
   <link>http://www.streetinsider.com/SEC+Filings/Form++3++++++++++IMMUNIC%2C+INC.+++++++++++++For%3A+Jun+01++Filed+by%3A+Lundgren+Erik/26585352.html</link>
   <description>si-local-file:///var/storage/secattach/20260601/26585352.html</description>
   <guid isPermaLink="true">http://www.streetinsider.com/SEC+Filings/Form++3++++++++++IMMUNIC%2C+INC.+++++++++++++For%3A+Jun+01++Filed+by%3A+Lundgren+Erik/26585352.html</guid>
   <pubDate>Mon, 01 Jun 2026 17:56:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">IMUX</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.02321652</category>
   	  </item>
  <item>
   <title>Form  DEF 14A    IMMUNIC, INC.             For: Jun 29</title>
   <link>http://www.streetinsider.com/SEC+Filings/Form++DEF+14A++++IMMUNIC%2C+INC.+++++++++++++For%3A+Jun+29/26575819.html</link>
   <description>si-local-file:///var/storage/secattach/20260529/26575819.html</description>
   <guid isPermaLink="true">http://www.streetinsider.com/SEC+Filings/Form++DEF+14A++++IMMUNIC%2C+INC.+++++++++++++For%3A+Jun+29/26575819.html</guid>
   <pubDate>Fri, 29 May 2026 16:33:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">IMUX</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.02321652</category>
   	  </item>
  <item>
   <title>Form  DEF 14A    IMMUNIC, INC.             For: Jun 29</title>
   <link>http://www.streetinsider.com/SEC+Filings/Form++DEF+14A++++IMMUNIC%2C+INC.+++++++++++++For%3A+Jun+29/26575819.html</link>
   <description>si-local-file:///var/storage/secattach/20260529/26575819.html</description>
   <guid isPermaLink="true">http://www.streetinsider.com/SEC+Filings/Form++DEF+14A++++IMMUNIC%2C+INC.+++++++++++++For%3A+Jun+29/26575819.html</guid>
   <pubDate>Fri, 29 May 2026 16:33:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">IMUX</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.02321652</category>
   	  </item>
  <item>
   <title>Form  8-K        IMMUNIC, INC.             For: May 28</title>
   <link>http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++IMMUNIC%2C+INC.+++++++++++++For%3A+May+28/26561003.html</link>
   <description>si-local-file:///var/storage/secattach/20260528/26561003.html</description>
   <guid isPermaLink="true">http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++IMMUNIC%2C+INC.+++++++++++++For%3A+May+28/26561003.html</guid>
   <pubDate>Thu, 28 May 2026 07:01:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">IMUX</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.02321652</category>
   	  </item>
  <item>
   <title>Form  8-K        IMMUNIC, INC.             For: May 28</title>
   <link>http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++IMMUNIC%2C+INC.+++++++++++++For%3A+May+28/26561003.html</link>
   <description>si-local-file:///var/storage/secattach/20260528/26561003.html</description>
   <guid isPermaLink="true">http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++IMMUNIC%2C+INC.+++++++++++++For%3A+May+28/26561003.html</guid>
   <pubDate>Thu, 28 May 2026 07:01:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">IMUX</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.02321652</category>
   	  </item>
  <item>
   <title>Immunic presents additional data on multiple sclerosis drug candidate</title>
   <link>http://www.streetinsider.com/FDA/Immunic+presents+additional+data+on+multiple+sclerosis+drug+candidate/26560756.html</link>
   <description>

&lt;p&gt;Immunic Inc. (NASDAQ: IMUX) announced the presentation of additional data from its Phase 2 CALLIPER trial evaluating vidofludimus calcium in patients with progressive multiple sclerosis at the 2026 Consortium of Multiple Sclerosis Centers Annual Meeting in Charlotte, NC.&lt;/p&gt;

&lt;p&gt;The company presented three posters, including a late-breaking analysis that introduced a unified statistical approach called Confirmed Disability Change (CDC) designed to capture both disability worsening and improvement within a single framework. The analysis applied three statistical models to CALLIPER trial data, with results consistently favoring vidofludimus calcium over placebo.&lt;/p&gt;

&lt;p&gt;A second poster examined patient-reported outcomes from the trial, including measures of depressive thoughts</description>
   <guid isPermaLink="true">http://www.streetinsider.com/FDA/Immunic+presents+additional+data+on+multiple+sclerosis+drug+candidate/26560756.html</guid>
   <pubDate>Thu, 28 May 2026 06:30:26 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">A.13662202</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.14320728</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.60012014</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">IMUX</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.00063751</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.02321652</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.20250741</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.21652449</category>
   	  </item>
  <item>
   <title>Immunic presents additional data on multiple sclerosis drug candidate</title>
   <link>http://www.streetinsider.com/FDA/Immunic+presents+additional+data+on+multiple+sclerosis+drug+candidate/26560756.html</link>
   <description>

&lt;p&gt;Immunic Inc. (NASDAQ: IMUX) announced the presentation of additional data from its Phase 2 CALLIPER trial evaluating vidofludimus calcium in patients with progressive multiple sclerosis at the 2026 Consortium of Multiple Sclerosis Centers Annual Meeting in Charlotte, NC.&lt;/p&gt;

&lt;p&gt;The company presented three posters, including a late-breaking analysis that introduced a unified statistical approach called Confirmed Disability Change (CDC) designed to capture both disability worsening and improvement within a single framework. The analysis applied three statistical models to CALLIPER trial data, with results consistently favoring vidofludimus calcium over placebo.&lt;/p&gt;

&lt;p&gt;A second poster examined patient-reported outcomes from the trial, including measures of depressive thoughts</description>
   <guid isPermaLink="true">http://www.streetinsider.com/FDA/Immunic+presents+additional+data+on+multiple+sclerosis+drug+candidate/26560756.html</guid>
   <pubDate>Thu, 28 May 2026 06:30:26 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">A.13662202</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.14320728</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.60012014</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">IMUX</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.00063751</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.02321652</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.20250741</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.21652449</category>
   	  </item>
  <item>
   <title>Immunic presents additional data on multiple sclerosis drug candidate</title>
   <link>http://www.streetinsider.com/FDA/Immunic+presents+additional+data+on+multiple+sclerosis+drug+candidate/26560756.html</link>
   <description>

&lt;p&gt;Immunic Inc. (NASDAQ: IMUX) announced the presentation of additional data from its Phase 2 CALLIPER trial evaluating vidofludimus calcium in patients with progressive multiple sclerosis at the 2026 Consortium of Multiple Sclerosis Centers Annual Meeting in Charlotte, NC.&lt;/p&gt;

&lt;p&gt;The company presented three posters, including a late-breaking analysis that introduced a unified statistical approach called Confirmed Disability Change (CDC) designed to capture both disability worsening and improvement within a single framework. The analysis applied three statistical models to CALLIPER trial data, with results consistently favoring vidofludimus calcium over placebo.&lt;/p&gt;

&lt;p&gt;A second poster examined patient-reported outcomes from the trial, including measures of depressive thoughts</description>
   <guid isPermaLink="true">http://www.streetinsider.com/FDA/Immunic+presents+additional+data+on+multiple+sclerosis+drug+candidate/26560756.html</guid>
   <pubDate>Thu, 28 May 2026 06:30:26 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">A.13662202</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.14320728</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.60012014</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">IMUX</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.00063751</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.02321652</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.20250741</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.21652449</category>
   	  </item>
  <item>
   <title>Immunic presents additional data on multiple sclerosis drug candidate</title>
   <link>http://www.streetinsider.com/FDA/Immunic+presents+additional+data+on+multiple+sclerosis+drug+candidate/26560756.html</link>
   <description>

&lt;p&gt;Immunic Inc. (NASDAQ: IMUX) announced the presentation of additional data from its Phase 2 CALLIPER trial evaluating vidofludimus calcium in patients with progressive multiple sclerosis at the 2026 Consortium of Multiple Sclerosis Centers Annual Meeting in Charlotte, NC.&lt;/p&gt;

&lt;p&gt;The company presented three posters, including a late-breaking analysis that introduced a unified statistical approach called Confirmed Disability Change (CDC) designed to capture both disability worsening and improvement within a single framework. The analysis applied three statistical models to CALLIPER trial data, with results consistently favoring vidofludimus calcium over placebo.&lt;/p&gt;

&lt;p&gt;A second poster examined patient-reported outcomes from the trial, including measures of depressive thoughts</description>
   <guid isPermaLink="true">http://www.streetinsider.com/FDA/Immunic+presents+additional+data+on+multiple+sclerosis+drug+candidate/26560756.html</guid>
   <pubDate>Thu, 28 May 2026 06:30:26 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">A.13662202</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.14320728</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.60012014</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">IMUX</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.00063751</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.02321652</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.20250741</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.21652449</category>
   	  </item>
  <item>
   <title>Immunic presents additional data on multiple sclerosis drug candidate</title>
   <link>http://www.streetinsider.com/FDA/Immunic+presents+additional+data+on+multiple+sclerosis+drug+candidate/26560756.html</link>
   <description>

&lt;p&gt;Immunic Inc. (NASDAQ: IMUX) announced the presentation of additional data from its Phase 2 CALLIPER trial evaluating vidofludimus calcium in patients with progressive multiple sclerosis at the 2026 Consortium of Multiple Sclerosis Centers Annual Meeting in Charlotte, NC.&lt;/p&gt;

&lt;p&gt;The company presented three posters, including a late-breaking analysis that introduced a unified statistical approach called Confirmed Disability Change (CDC) designed to capture both disability worsening and improvement within a single framework. The analysis applied three statistical models to CALLIPER trial data, with results consistently favoring vidofludimus calcium over placebo.&lt;/p&gt;

&lt;p&gt;A second poster examined patient-reported outcomes from the trial, including measures of depressive thoughts</description>
   <guid isPermaLink="true">http://www.streetinsider.com/FDA/Immunic+presents+additional+data+on+multiple+sclerosis+drug+candidate/26560756.html</guid>
   <pubDate>Thu, 28 May 2026 06:30:26 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">A.13662202</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.14320728</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.60012014</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">IMUX</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.00063751</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.02321652</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.20250741</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.21652449</category>
   	  </item>
  <item>
   <title>Immunic presents additional data on multiple sclerosis drug candidate</title>
   <link>http://www.streetinsider.com/FDA/Immunic+presents+additional+data+on+multiple+sclerosis+drug+candidate/26560756.html</link>
   <description>

&lt;p&gt;Immunic Inc. (NASDAQ: IMUX) announced the presentation of additional data from its Phase 2 CALLIPER trial evaluating vidofludimus calcium in patients with progressive multiple sclerosis at the 2026 Consortium of Multiple Sclerosis Centers Annual Meeting in Charlotte, NC.&lt;/p&gt;

&lt;p&gt;The company presented three posters, including a late-breaking analysis that introduced a unified statistical approach called Confirmed Disability Change (CDC) designed to capture both disability worsening and improvement within a single framework. The analysis applied three statistical models to CALLIPER trial data, with results consistently favoring vidofludimus calcium over placebo.&lt;/p&gt;

&lt;p&gt;A second poster examined patient-reported outcomes from the trial, including measures of depressive thoughts</description>
   <guid isPermaLink="true">http://www.streetinsider.com/FDA/Immunic+presents+additional+data+on+multiple+sclerosis+drug+candidate/26560756.html</guid>
   <pubDate>Thu, 28 May 2026 06:30:26 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">A.13662202</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.14320728</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.60012014</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">IMUX</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.00063751</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.02321652</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.20250741</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.21652449</category>
   	  </item>
  <item>
   <title>Immunic presents additional data on multiple sclerosis drug candidate</title>
   <link>http://www.streetinsider.com/FDA/Immunic+presents+additional+data+on+multiple+sclerosis+drug+candidate/26560756.html</link>
   <description>

&lt;p&gt;Immunic Inc. (NASDAQ: IMUX) announced the presentation of additional data from its Phase 2 CALLIPER trial evaluating vidofludimus calcium in patients with progressive multiple sclerosis at the 2026 Consortium of Multiple Sclerosis Centers Annual Meeting in Charlotte, NC.&lt;/p&gt;

&lt;p&gt;The company presented three posters, including a late-breaking analysis that introduced a unified statistical approach called Confirmed Disability Change (CDC) designed to capture both disability worsening and improvement within a single framework. The analysis applied three statistical models to CALLIPER trial data, with results consistently favoring vidofludimus calcium over placebo.&lt;/p&gt;

&lt;p&gt;A second poster examined patient-reported outcomes from the trial, including measures of depressive thoughts</description>
   <guid isPermaLink="true">http://www.streetinsider.com/FDA/Immunic+presents+additional+data+on+multiple+sclerosis+drug+candidate/26560756.html</guid>
   <pubDate>Thu, 28 May 2026 06:30:26 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">A.13662202</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.14320728</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.60012014</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">IMUX</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.00063751</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.02321652</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.20250741</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.21652449</category>
   	  </item>
  <item>
   <title>Immunic presents additional data on multiple sclerosis drug candidate</title>
   <link>http://www.streetinsider.com/FDA/Immunic+presents+additional+data+on+multiple+sclerosis+drug+candidate/26560756.html</link>
   <description>

&lt;p&gt;Immunic Inc. (NASDAQ: IMUX) announced the presentation of additional data from its Phase 2 CALLIPER trial evaluating vidofludimus calcium in patients with progressive multiple sclerosis at the 2026 Consortium of Multiple Sclerosis Centers Annual Meeting in Charlotte, NC.&lt;/p&gt;

&lt;p&gt;The company presented three posters, including a late-breaking analysis that introduced a unified statistical approach called Confirmed Disability Change (CDC) designed to capture both disability worsening and improvement within a single framework. The analysis applied three statistical models to CALLIPER trial data, with results consistently favoring vidofludimus calcium over placebo.&lt;/p&gt;

&lt;p&gt;A second poster examined patient-reported outcomes from the trial, including measures of depressive thoughts</description>
   <guid isPermaLink="true">http://www.streetinsider.com/FDA/Immunic+presents+additional+data+on+multiple+sclerosis+drug+candidate/26560756.html</guid>
   <pubDate>Thu, 28 May 2026 06:30:26 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">A.13662202</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.14320728</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.60012014</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">IMUX</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.00063751</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.02321652</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.20250741</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.21652449</category>
   	  </item>
  <item>
   <title>Immunic presents phase 2 trial data at multiple sclerosis meeting</title>
   <link>http://www.streetinsider.com/FDA/Immunic+presents+phase+2+trial+data+at+multiple+sclerosis+meeting/26560754.html</link>
   <description>

&lt;p&gt;Immunic Inc. (NASDAQ: IMUX) presented additional data from its phase 2 CALLIPER trial of vidofludimus calcium for progressive multiple sclerosis at the Consortium of Multiple Sclerosis Centers Annual Meeting in Charlotte, NC.&lt;/p&gt;

&lt;p&gt;The company presented three posters, including a late-breaking analysis introducing a unified statistical approach called Confirmed Disability Change that measures both disability worsening and improvement. The analysis applied three statistical models to CALLIPER trial data, with results favoring vidofludimus calcium over placebo across all approaches.&lt;/p&gt;

&lt;p&gt;Patient-reported outcomes data showed PHQ-9 depression scores improved numerically in both treatment groups through 120 weeks, with no indication of worsening depressive thoughts with vidofludimus</description>
   <guid isPermaLink="true">http://www.streetinsider.com/FDA/Immunic+presents+phase+2+trial+data+at+multiple+sclerosis+meeting/26560754.html</guid>
   <pubDate>Thu, 28 May 2026 06:30:25 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">A.13662202</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.14320728</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.60012014</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">IMUX</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.00063751</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.02321652</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.20250741</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.21652449</category>
   	  </item>
 </channel>
</rss>
